Table 2. Population and calculated... | American Society of Hematology

Table 2.

Population and calculated estimated sample sizes

Trial	Comparator, n	MANIFEST arm 3 including IPSS int-1 patients, n	MANIFEST arm 3 excluding IPSS int-1 patients, n	ESS including IPSS int-1 patients, n	ESS excluding IPSS int-1 patients, n
COMFORT-I	155	80	69	19.21	14.77
COMFORT-II	146	80	69	22.10	14.87
JAKARTA 400 mg	96	80	69	19.69	8.71
JAKARTA 500 mg	97	80	69	31.37	22.54
SIMPLIFY-1 ruxolitinib	217	80	69	34.61	34.61
SIMPLIFY-1 momelotinib	215	80	69	33.40	33.40

Trial	Comparator, n	MANIFEST arm 3 including IPSS int-1 patients, n	MANIFEST arm 3 excluding IPSS int-1 patients, n	ESS including IPSS int-1 patients, n	ESS excluding IPSS int-1 patients, n
COMFORT-I	155	80	69	19.21	14.77
COMFORT-II	146	80	69	22.10	14.87
JAKARTA 400 mg	96	80	69	19.69	8.71
JAKARTA 500 mg	97	80	69	31.37	22.54
SIMPLIFY-1 ruxolitinib	217	80	69	34.61	34.61
SIMPLIFY-1 momelotinib	215	80	69	33.40	33.40

Int-1, intermediate-1 risk.